Pimecrolimus (SDZ ASM 981)

Literatur

• 1 Bochelen D, Rudin M, Sauter A. Calcineurin inhibitors FK506 and SDZ ASM 981 alleviate the outcome of focal cerebral ischemic/reperfusion injury.  J Pharmacol Exp Ther. 1999;  288 653-659
• 2 Bornhövd E C, Burgdorf W H, Wollenberg A. Macrolactam immunomodulators for topical treatment of inflammatory skin diseases.  J Am Acad Dermatol. 2001;  45 736-743
• 3 Flanagan W M, Corthlsy B, Bram R J, Crabtree G R. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A.  Nature. 1991;  352 803-807
• 4 Grassberger M, Baumruker T, Enz A. et al . A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology.  Br J Dermatol. 1999;  141 264-273
• 5 Harper J, Green A, Scott G, Gruendl E, Dorobek B, Cardno M, Burtin P. First experience of topical SDZ ASM 981 in children with atopic dermatitis.  Br J Dermatol. 2001;  144 781-787
• 6 Hultsch T, Muller K D, Meingassner J G, Grassberger M, Schopf R E, Knop J. Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized Cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner.  Arch Dermatol Res. 1998;  290 501-507
• 7 Kay J E. Structure-function relationships in the FK506-binding protein (FKBP) family of peptidylprolyl cis-trans isomerases.  Biochem J. 1996;  314 361-385
• 8 Liu J. FK506 and cyclosporin, molecular probes for studying intracellular signal transduction.  Immunol Today. 1993;  14 290-295
• 9 Luger T, Van Leent E J, Graeber M. et al . SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis.  Br J Dermatol. 2001;  144 788-794
• 10 Luger T. Treatment of immune-mediated skin diseases: future perspectives.  Eur J Dermatol. 2001;  11 343-347
• 11 Meingassner J G, Grassberger M, Fahrngruber H, Moore H D, Schuurman H, Stutz A. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology.  Br J Dermatol. 1997;  137 568-576
• 12 Mrowietz U, Graeber M, Brautigam M. et al . The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion.  Br J Dermatol. 1998;  139 992-996
• 13 Neckermann G, Bavandi A, Meingassner J G. Atopic dermatitis-like symptoms in hypomagnesaemic hairless rats are prevented and inhibited by systemic or topical SDZ ASM 981.  Br J Dermatol. 2000;  142 669-679
• 14 Paul C, Graeber M, Stuetz A. Ascomycins: promising agents for the treatment of inflammatory skin diseases.  Expert Opin Investig Drugs. 2000;  9 69-77
• 15 Queille-Roussel C, Graeber M, Thurston M. et al . SDZ ASM 981 is the first non-steroid that suppresses established nickel contact dermatitis elicited by allergen challenge.  Contact Dermatitis. 2000;  42 349-350
• 16 Queille-Roussel C, Paul C, Duteil L. et al . The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study.  Br J Dermatol. 2001;  144 507-513
• 17 Rappersberger K, Meingassner J G, Fialla R, Fodinger D, Sterniczky B, Rauch S, Putz E, Stutz A, Wolff K. Clearing of psoriasis by a novel immunsuppressive macrolide.  J Invest Dermatol. 1996;  106 701-710
• 18 Rappersberger K, Komar M, Ebelin M E. Oral SDZ ASM 981: Safety, pharmacokinetics and efficacy in patients with moderate to severe chronic plaque psoriasis.  J Invest Dermatol. 2000;  114 776
• 19 Sullivan J R, Kossard S. Acquired scalp alopecia. Part II: A review.  Australas J Dermatol. 1999;  40 61-70
• 20 Van Leent E JM, Graber M, Thurston M, Wagenaar A, Spuls P I, Bos J D. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis.  Arch Dermatol. 1998;  134 805-809
• 21 Van Leent E JM, Ebelin M E, Burtin P. Low systemic concentrations of SDZ ASM 981 after topical treatment of extensive atopic dermatits lesions.  J Eur Acad Dermatol Venereol. 1998;  11 S123-124
• 22 Zuberbier T, Chong S U, Grunow K. et al . The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils.  J Allergy Clin Immunol. 2001;  108 275-280